Back to results
US 8,822,645 B2Granted
Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
AssigneeAbbVie Inc.
InventorsTariq Ghayur, Jijie Gu, Peter C. Isakson
Life of this patent
Estimating the term…
Abstract
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
Claims39
A binding protein comprising first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C-(X2)n, wherein
- VD1 is a first variable domain;
- VD2 is a second variable domain;
- C is a constant domain;
- X1 is a linker;
- X2 is an Fc region;
- and
- n is 0 or 1;
- wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site,
- wherein the binding protein binds to PGE2 and another target,
- and wherein the variable domains that form a functional binding site for PGE2 comprise SEQ ID NO:
- 110 or 111.
8 more elements
A binding protein comprising first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C-(X2)n, wherein
- VD1 is a first variable domain;
- VD2 is a second variable domain;
- C is a constant domain;
- X1 is a linker;
- X2 is an Fc region;
- and
- n is 0 or 1;
- wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site;
- and wherein the binding protein binds:
- (a) TNF and PGE2, wherein:
- (1) the variable domains that form a functional binding site for TNF comprise SEQ ID NO:
- 112 or 113;
- and
- (2) the variable domains that form a functional binding site for PGE2 comprise SEQ ID NO:
- 110 or 111;
- (b) NGF and PGE2, wherein:
- (1) the variable domains that form a functional binding site for NGF comprise SEQ ID NO:
- 32 or 33;
- and
- (2) the variable domains that form a functional binding site for PGE2 comprise SEQ ID NO:
- 48 or 49;
- (c) IL-17A and PGE2, wherein:
- (1) the variable domains that form a functional binding site for IL-17A comprise SEQ ID NO:
- 34 or 35;
- and
- (2) the variable domains that form a functional binding site for PGE2 comprise SEQ ID NO:
- 48 or 49;
- (d) IL-1b and PGE2, wherein:
- (1) the variable domains that form a functional binding site for IL-1b comprise SEQ ID NO:
- 36 or 37;
- and
- (2) the variable domains that form a functional binding site for PGE2 comprise SEQ ID NO:
- 48 or 49;
- (e) IL-6R and PGE2, wherein:
- (1) the variable domains that form a functional binding site for IL-6R comprise SEQ ID NO:
- 54 or 55;
- and
- (2) the variable domains that form a functional binding site for PGE2 comprise SEQ ID NO:
- 48 or 49;
- (f) VEGF and PGE2, wherein:
- (1) the variable domains that form a functional binding site for VEGF comprise SEQ ID NO:
- 28 or 29;
- and
- (2) the variable domains that form a functional binding site for PGE2 comprise SEQ ID NO:
- 48 or 49;
- (g) Abeta and PGE2, wherein:
- (1) the variable domains that form a functional binding site for Abeta comprise SEQ ID NO:
- 40 or 41;
- and
- (2) the variable domains that form a functional binding site for PGE2 comprise SEQ ID NO:
- 48 or 49;
- or
- (h) IL-15 and PGE2, wherein:
- (1) the variable domains that form a functional binding site for IL-15 comprise SEQ ID NO:
- 50 or 51;
- and
- (2) the variable domains that form a functional binding site for PGE2 comprise SEQ ID NO:
- 48 or 49.
55 more elements
A binding protein comprising first and second polypeptide chains, wherein the binding protein binds to a target pair selected from:
- (a) TNF and PGE2, wherein the binding protein comprises
- DVD HU2B5.7SLD2E7 (comprising SEQ ID NOs:
- 114 and 115),
- DVD HU2B5.7LLD2E7 (comprising SEQ ID NOs:
- 116 and 117),
- DVD D2E7SLHU2B5.7 (comprising SEQ ID NOs:
- 118 and 119), or
- DVD D2E7LLHU2B5.7 (comprising SEQ ID NOs:
- 120 and 121);
- (b) NGF and PGE2, wherein the binding protein comprises
- DVD 164 (comprising SEQ ID NOs:
- 132 and 133), or
- DVD 163 (comprising SEQ ID NOs:
- 134 and 135);
- (c) IL-17A and PGE2, wherein the binding protein comprises
- DVD 156 (comprising SEQ ID NOs:
- 136 and 137), or
- DVD 155 (comprising SEQ ID NOs:
- 138 and 139);
- (d) IL-1b and PGE2, wherein the binding protein comprises
- DVD 158 (comprising SEQ ID NOs:
- 140 and 141), or
- DVD 157 (comprising SEQ ID NOs:
- 142 and 143);
- (e) IL-6R and PGE2, wherein the binding protein comprises
- DVD 250 (comprising SEQ ID NOs:
- 144 and 145), or
- DVD 249 (comprising SEQ ID NOs:
- 146 and 147;
- (f) VEGF and PGE2, wherein the binding protein comprises
- DVD 162 (comprising SEQ ID NOs:
- 128 and 129), or
- DVD 161 (comprising SEQ ID NOs:
- 130 and 131);
- (g) Abeta and PGE2, wherein the binding protein comprises
- DVD 227 (comprising SEQ ID NOs:
- 148 and 149), or
- DVD 228 (comprising SEQ ID NOs:
- 150 and 151);
- and
- (h) IL-15 and PGE2, wherein the binding protein comprises
- DVD 154 (comprising SEQ ID NOs:
- 164 and 165), or
- DVD 153 (comprising SEQ ID NOs:
- 166 and 167).
42 more elements
Dependencies are inferred from the claim text.